fibrosis Archives | InSphero

fibrosis

September 23, 2019

Can an in vitro NASH endpoint be truly predictive of the in vivo response?

Model systems, whether laboratory animals or human cell-based systems, have long been central to the discovery and development of new and better drugs for the treatment of human disease. But […]
July 30, 2019

Are Animal NASH models slowing us down?

InSphero Senior Application Scientist Sue Grepper explains why critical limitations of dietary and genetically modified rodent models for NASH may be slowing down drug discovery efforts in this blog.  She […]
July 17, 2019

Can we really find a cure for NASH without the scalability of in vitro NASH models?

InSphero CEO Jan Lichtenberg and renowned liver disease expert Dr. Scott Friedman of the Icahn School of Medicine at Mount Sinai recently talked to PharmaExec magazine about how to resolve […]
August 20, 2018

Can 3D in vitro models deliver what pharma needs for NASH and Fibrosis drug discovery?

Pharma companies racing to develop new drugs to combat chronic liver diseases, such as NASH and fibrosis, need better preclinical testing tools for compound screening and mechanistic studies. Here’s how […]